OBJECTIVES:  Currently, there is scarce data from clinical trials estimating and comparing utilities and quality-adjusted life years (QALYs) measurements after tree usual therapeutic strategies for multivessel coronary artery disease (CAD). This study describes and compares utility and QALYs measures for CAD patients assigned to medical treatment (MT), percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). METHODS: Utility and QALYs were obtained from 579 patients from MASS II study, a randomized prospective study. To obtain utilities, the items of the 36-Item Short-Form (SF-36) were converted into a six-dimensional health state classification system, the SF-6D. The interviews were administered at baseline and at six, 12, 24, 36, 48 and 60 months of follow-up. RESULTS: The median cumulative utility scores along the five years was 0.8090 (95% CI, 0.8035-0.8090) for patients assigned to PCI, 0.7710 (95% CI, 0.7620-0.7840) to MT and 0.7830 (95% CI, 0.7710-0.7970) to CABG, which were significantly different among all groups (p < 0.05, Dunn test). The median cumulative QALYs along the five years was 4.015 (95% CI, 3.9150-4.1050) for PCI, 3.8320 (95% CI, 3.7555-3.9110) to MT and 3.9840 (95% CI, 3.8815-4.0575) to CABG. Additionally, the median QALYs gained between PCI vs. MT was 0.183, CABG vs. MT was 0.152 and PCI vs. CABG was 0.031. Diabetes and functional class subgroups did not influenced the results. CONCLUSIONS:  Considering the preference-based measures as a support for decision-making process, PCI showed to be the treatment with higher cumulative quality of life among multivessel CAD patients compared to CABG and MT. The results presented constitute valuable data for further cost-utility studies. STUDY ASSOCIATION This abstract is part of the doctoral thesis of Sara Michelly G Brandao by Programa de Pós-Graduação em Cardiologia da Faculdade de Medicina da Universidade de São Paulo.